Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorOld Dominion University
About this trial
The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.
Eligibility criteria
Qualifiers
Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %.
Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session).
Able and willing to comply with study procedures and provide informed consent.
Disqualifiers
Co-morbidity expected to limit survival (e.g., terminal illness).
End-stage renal disease.
Unstable fluid overload.
Current pregnancy (self-disclose).
Trial design
Treatments tested in this trial
- Extra-virgin olive oil
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov